Unity Historical Balance Sheet
UBX Stock | USD 1.19 0.05 4.39% |
Trend analysis of Unity Biotechnology balance sheet accounts such as Total Assets of 100.2 M, Other Current Liab of 5.5 M, Total Current Liabilities of 14.3 M or Total Stockholder Equity of 27 M provides information on Unity Biotechnology's total assets, liabilities, and equity, which is the actual value of Unity Biotechnology to its prevalent stockholders. By breaking down trends over time using Unity Biotechnology balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Unity Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Unity Biotechnology is a good buy for the upcoming year.
Unity |
About Unity Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Unity Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Unity Biotechnology Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Unity Biotechnology and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Unity currently owns. An asset can also be divided into two categories, current and non-current.
Unity Biotechnology Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Unity Biotechnology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Unity Biotechnology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Unity Biotechnology balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Unity Biotechnology are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Unity Biotechnology's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Unity Biotechnology current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unity Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy Unity Stock please use our How to Invest in Unity Biotechnology guide.At this time, Unity Biotechnology's Common Stock Shares Outstanding is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 100.2 M in 2024, whereas Total Stockholder Equity is likely to drop slightly above 27 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 7.0M | 5.3M | 3.0M | 5.5M | Total Assets | 124.7M | 124.4M | 65.7M | 100.2M |
Unity Biotechnology balance sheet Correlations
Click cells to compare fundamentals
Unity Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Unity Biotechnology balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 151.2M | 156.3M | 124.7M | 124.4M | 65.7M | 100.2M | |
Other Current Liab | 12.0M | 7.4M | 7.0M | 5.3M | 3.0M | 5.5M | |
Total Current Liabilities | 17.2M | 14.5M | 16.6M | 19.6M | 7.8M | 14.3M | |
Total Stockholder Equity | 120.7M | 82.9M | 59.6M | 66.8M | 28.4M | 27.0M | |
Other Liab | 3.3M | 4.1M | 13.3M | 23K | 26.5K | 25.1K | |
Net Tangible Assets | 120.7M | 82.9M | 59.6M | 66.8M | 76.9M | 57.5M | |
Property Plant And Equipment Net | 16.6M | 36.1M | 31.2M | 26.9M | 18.1M | 19.9M | |
Net Debt | (37.4M) | 41.2M | 18.7M | 34.6M | 7.2M | 7.5M | |
Retained Earnings | (245.5M) | (339.3M) | (400.0M) | (460.0M) | (484.4M) | (460.1M) | |
Accounts Payable | 5.2M | 2.6M | 2.0M | 1.8M | 1.4M | 2.1M | |
Cash | 37.5M | 17.8M | 32.9M | 12.7M | 19.8M | 23.3M | |
Non Current Assets Total | 21.7M | 55.5M | 34.2M | 27.8M | 19.1M | 25.2M | |
Non Currrent Assets Other | 2.1M | 1.4M | 987K | 52K | 1.0M | 981.1K | |
Other Assets | 2.1M | 1.4M | 987K | 948K | 853.2K | 992.6K | |
Cash And Short Term Investments | 127.5M | 97.7M | 88.1M | 94.8M | 43.2M | 79.8M | |
Common Stock Shares Outstanding | 4.4M | 5.1M | 5.6M | 9.5M | 14.8M | 15.5M | |
Short Term Investments | 90.0M | 79.9M | 55.2M | 82.1M | 23.4M | 22.2M | |
Liabilities And Stockholders Equity | 151.2M | 156.3M | 124.7M | 124.4M | 65.7M | 100.2M | |
Non Current Liabilities Total | 13.3M | 59.0M | 48.5M | 37.9M | 29.5M | 33.0M | |
Capital Surpluse | 324.7M | 366.7M | 422.4M | 527.0M | 606.1M | 636.4M | |
Other Current Assets | 2.0M | 6.3M | 2.4M | 1.5M | 1.8M | 2.1M | |
Other Stockholder Equity | 366.1M | 422.2M | 459.6M | 500.8M | 512.8M | 355.1M | |
Total Liab | 30.5M | 73.4M | 65.1M | 57.5M | 37.3M | 43.4M | |
Property Plant And Equipment Gross | 16.6M | 12.6M | 31.2M | 26.9M | 27.3M | 17.9M | |
Total Current Assets | 129.5M | 100.9M | 90.5M | 96.5M | 46.6M | 81.9M | |
Accumulated Other Comprehensive Income | 90K | 5K | (44K) | (251K) | (24K) | (25.2K) | |
Common Stock | 3K | 4K | 5K | 6K | 2K | 3.7K | |
Property Plant Equipment | 16.6M | 36.1M | 31.2M | 7.8M | 9.0M | 16.9M | |
Net Invested Capital | 120.7M | 107.4M | 81.0M | 87.2M | 28.4M | 27.0M | |
Net Working Capital | 112.3M | 86.4M | 73.9M | 76.9M | 38.8M | 71.5M | |
Short Long Term Debt Total | 45K | 59.0M | 51.6M | 47.4M | 27.0M | 33.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unity Stock Analysis
When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.